Business Wire

MA-ECHOSENS

15.11.2021 14:58:06 CET | Business Wire | Press release

Share
World Diabetes Day and American Diabetes Month: Echosens Highlights Link Between Diabetes and Liver Disease, Urges Non-Invasive Detection and Monitoring

Echosens , a high-technology company offering the FibroScan® family of products, recognizes the importance of World Diabetes Day (WDD), Nov. 14 and the month of November as American Diabetes Month for bringing greater focus to the impact of Type 2 diabetes and its link to metabolic syndrome (MetS) and nonalcoholic fatty liver disease (NAFLD). MetS is a cluster of risk factors specific for cardiovascular disease, and NAFLD is the accumulation of liver fat in people who drink little or no alcohol. Obesity is the most frequently observed component of MetS.

“WWD, a three-year campaign to improve access to diabetes care and prevent diabetes, and the American Diabetes Month present opportunities to highlight how obesity increases the risk for Type 2 diabetes, liver disease, MetS and heart disease,” says Dominique Legros, Echosens Group CEO. “Fat in the liver can increase the risks of progression of prediabetes to overt disease. Once a patient has fatty liver disease, diabetes may become more difficult to control, making it critical to obtain an early diagnosis and introduce lifestyle changes to halt or reverse NAFLD.”

NAFLD has 70% prevalence among Type 2 diabetes patients, and people living with Type 2 diabetes and NAFLD are at a two-fold risk of all-cause mortality versus those living with Type 2 diabetes alone. In the United States, 36.5% of adults are obese, while another 32.5% of American adults are overweight. Globally, about 13% of the world’s adult population has obesity and about 39% are overweight, according to the World Health Organization’s most recent statistics.

FibroScan, a painless, non-invasive exam at the point of care can measure and monitor the amount of liver stiffness and detect NAFLD in its earliest stages when the individual may be asymptomatic. It can be used to rule out the need for further assessment, such as a painful liver biopsy, saving time and resources for people who don’t need further assessment.

“The good news is that even moderate weight loss can significantly reduce liver fat in patients with NAFLD and play an essential role in the prevention and treatment of Type 2 diabetes,” adds Dominique Legros. “This November, we urge everyone touched by the growing liver disease epidemic to help promote advocacy efforts throughout the year and confront diabetes as a critical global health issue.”

To learn more, read “Early Detection, Healthy Diet and Lifestyle Changes Critical for Addressing Metabolic Syndrome and Halting Progression of Liver Disease .”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140+ international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/

Link:

ClickThru

Social Media:

https://www.facebook.com/fibroscan.echosens

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ExaGrid Announces Record 3rd Quarter Bookings and Revenue13.10.2026 14:00:00 CEST | Press release

ExaGrid Achieves 23rd Consecutive Quarter of Free Cash Flow, EBITDA, and P&L Positive Operations ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the fastest backups, fastest restores, largest backup storage scale-out system with deduplication, and the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it had its best ever third quarter for bookings and revenue in the quarter ending September 30, 2026, with double-digit revenue growth over Q3 of 2025 and double-digit revenue growth for the first nine months of 2026 over 2025. ExaGrid has exceeded its plan in all three quarters of 2026 and is ahead of plan on its way to a record bookings and revenue year. ExaGrid’s growth rate is accelerating. In addition, ExaGrid remained P&L, EBITDA, and free cash flow positive for the 23rd consecutive quarter. The company is 100% debt-free, demonstrating strong financial health as a company.

Seequent Launches AI-Powered Imago Image Analysis to Accelerate Geological Core Logging13.10.2026 14:00:00 CEST | Press release

New AI capability embedded directly into Imago workflows transforms drill core imagery into consistent, quantitative geological data in minutes, helping exploration teams make more confident drilling decisions Seequent, The Bentley Subsurface Company, has launched Imago image analysis, a new AI-powered capability built directly into its cloud-based solution Imago for extracting knowledge from geoscientific imagery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013282684/en/ Imago image analysis results showing core condition, fracture polylines, and AutoCrop boundaries on diamond-drilled core. Core condition delineates solid (blue), broken (orange), depth blocks (green), and gaps in recovered core. With the new Imago image analysis add-on, geologists can analyse drill core imagery in minutes, dramatically accelerating analysis that has traditionally taken days or weeks. It generates consistent, high-confidence quantitati

What Europeans Really Want From Their Next Smartphone13.10.2026 13:01:00 CEST | Press release

New research from Samsung shows that Europeans are choosing smartphones with two things in mind: their life today and what they want to do next If you’ve ever bought running shoes for the runner you hoped to become or luggage for a yet to be planned trip, you’re not alone. New research from Samsung reveals that Europeans1 take a similar aspirational approach when choosing a smartphone. More than two thirds (66%2) of Europeans surveyed1 chose their current smartphone with at least one interest they wanted to pursue in mind, with interests ranging from entertainment and side hustles to gaming, travel and content creation. In fact, almost half (46%3) consider their ambitions when making technology choices, including 24% who say their choices are primarily shaped by the life they aspire to lead. Additionally, almost a third (28%) reported that they chose their current smartphone to better reflect their personal style. Having a variety of options to choose from is important when considering

Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules13.10.2026 13:00:00 CEST | Press release

Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform. Enodia’s proprietary platform enables selective Sec61 Translocon modulation, a novel approach to inhibit disease-driving proteins at the point of synthesis before pathological effects occur, while preserving essential physiological functions. Enodia has built a broad and well-characterized chemical space spanning multiple Sec61 inhibitor families, supported by extensive biological datasets, including proteomics, cryo-EM and tailored cell-line libraries that enable rational small-molecule design powered by machine learning. “Enodia has built a broad platform t

TradingHub Appoints Phil Snow as Chairman13.10.2026 11:00:00 CEST | Press release

TradingHub today announced the appointment of Phil Snow as Chairman, further strengthening the company's leadership as it continues to expand its global presence and invest in innovation across trade surveillance. Phil brings three decades of experience in financial technology, data and analytics, built at FactSet, where he served as Chief Executive Officer from 2015 to 2025. Under his leadership, FactSet more than doubled its revenue, joined the S&P 500 and expanded its products and global presence. The appointment follows TradingHub's recent investment from Nordic Capital and reflects the shared ambition to support the company's next phase of growth while building on the strong foundations established by its leadership team. "Phil is an outstanding appointment for TradingHub, and I am delighted to welcome him as Chairman," said Mike Coats, Chief Executive Officer of TradingHub. "He spent a decade running a global financial data company that serves many of the same institutions we do,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye